<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The results for 49 patients with hematologic and non <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> who were subjected to a cord blood transplantation from HLA-mismatched unrelated donors (UCBT) are presented here </plain></SENT>
<SENT sid="1" pm="."><plain>This retrospective study included 22 patients with <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo>, 12 with <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo>, one each with <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo>, <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, and juvenile myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo>, three with Wistott-<z:e sem="disease" ids="C0043194" disease_type="Disease or Syndrome" abbrv="">Aldrich syndrome</z:e>, three with <z:e sem="disease" ids="C0162309" disease_type="Disease or Syndrome" abbrv="ALD">adrenoleukodystrophy</z:e>, two with <z:e sem="disease" ids="C0026705" disease_type="Disease or Syndrome" abbrv="">Hunter's syndrome</z:e>, one each with <z:e sem="disease" ids="C0086795" disease_type="Disease or Syndrome" abbrv="">Hurler's syndrome</z:e>, <z:chebi fb="0" ids="26395">purine nucleotide</z:chebi> phosphorylase deficiency, pure red cell <z:mpath ids='MPATH_58'>aplasia</z:mpath>, and severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>In malignant diseases, the Kaplan-Meier estimates for three-year overall survival (OAS) and event-free survival (EFS) were 51.9 +/- 17.8, and 51.4 +/- 17.8%, respectively </plain></SENT>
<SENT sid="3" pm="."><plain>In patients with non malignant disease, the Kaplan-Meier estimates for three-year OAS and EFS were 64.2 +/- 28.8, and 37.5 +/- 29.4%, respectively </plain></SENT>
<SENT sid="4" pm="."><plain>In patients with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e>, the HLA disparity had no effect on OAS, EFS, incidence of <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e>, or engraftment </plain></SENT>
<SENT sid="5" pm="."><plain>On the other hand, for engraftment, the use of UCBT from HLA-mismatched unrelated donors may require a larger study in patients with non-malignant diseases </plain></SENT>
</text></document>